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ABSTRACT
Background The National Institute for Health and
Care Excellence 2008 guidelines on the treatment and
management of familial hypercholesterolaemia (FH)
recommend that children with FH should be considered
for statin treatment by the age of 10 years. The
Paediatric FH Register was established in 2012 to collect
baseline and long-term follow-up data on all children
with FH in the UK.
Methods Paediatricians and adult lipidologists have
been invited to enter baseline data on any child with a
clinical diagnosis of FH using an electronic capture
record.
Results Baseline data is on 232 children (50% boys,
80% Caucasian), with an untreated mean (SD) total
cholesterol of 7.61 (1.48) mmol/L and low-density
lipoprotein cholesterol (LDL-C) of 5.67 (1.46) mmol/L.
Overall 111/232 (47.8%) of the children were on statins.
Children over the age of 10 years at the most recent
follow-up were twice as likely to be on statin treatment
than those under 10 years (57.6% (102/177) vs 23.1%
(9/39), p=0.00009). In both age groups, those
subsequently on statin treatment had signiﬁcantly higher
diagnostic total and LDL-C (overall 6.01 (1.46) mmol/L
vs 5.31 (1.37) mmol/L, p=0.00007), and had stronger
evidence of a family history of early coronary heart
disease (CHD) in parent or ﬁrst-degree relative (overall
28.4% vs 19.0%, p=0.09). In statin-treated children
LDL-C level was reduced by 35% (2.07 (1.38) mmol/L)
compared with a reduction of 5.5% (0.29 (0.87) mmol/
L), p=0.0001 in those not treated. None of those on
statin had measured plasma levels of creatine kinase,
alanine aminotransferase and AST indicative of statin
toxicity (ie, >2.5 times the upper limit of the normal
range).
Conclusions The data indicates that treatment
decisions in children with FH are appropriately based on
a stronger family history of CHD and higher LDL-C.
BACKGROUND
Familial hypercholesterolaemia (FH) is an auto-
somal dominant inherited disorder characterised by
elevated low-density lipoprotein cholesterol
(LDL-C) levels from birth.1 The prevalence of het-
erozygous FH (HeFH) is thought to be 1 in 500,
although recent studies have indicated the preva-
lence may be twice as high.2 3 HeFH is therefore
estimated to affect 20–40 million people world-
wide. In patients with HeFH, premature coronary
heart disease (CHD) manifests in about half of men
by age 50 years and a third of women by age 60
years,4 however, the vast majority of patients with
HeFH remain undiagnosed. In the UK, based on a
prevalence of 1:500 and the known population age
structure, ∼14 000 children under the age of
10 years will have HeFH, with an additional
14 000 between the age of 10–18 years. The 2010
UK National FH audit data suggested that less than
800 of these have been identiﬁed and are being
clinically managed.5
In the UK the 2008 National Institute for Health
and Care Excellence (NICE) FH guideline (CG71)
recommended the use of the Simon Broome cri-
teria for diagnosing children with FH,6 using a
total cholesterol (TC) of >6.7 mmol/L and an
LDL-C of >4.0 mmol/L, together with a family
history of elevated TC and premature CHD. In
adults with a personal or family history of tendon
xanthomas (TX) a diagnosis of deﬁnite FH (DFH)
is given, while if TX are absent a diagnosis of pos-
sible FH (PFH) is given.4 Since TX usually develop
only in the third decade of life the DFH/PFH dis-
tinction is not used for children. The plasma total
and LDL-C levels that are used as diagnostic
What is already known on this topic
▸ Children with a clinical diagnosis of familial
hypercholesterolaemia (FH) have elevated levels
of low-density lipoprotein cholesterol from
birth, and elevated future risk of early coronary
heart disease.
▸ CG71 recommends that all children with FH
should be considered for treatment with a
statin by the age of 10 years using clinical
judgement.
▸ The National Institute for Health and Care
Excellence (NICE) Guideline CG71 recommends
all children with FH should have a DNA test to
conﬁrm their diagnosis.
What this study adds
▸ This is the largest group of UK children
examined to date with a clinical diagnosis of
familial hypercholesterolaemia (FH).
▸ Children less than 10 years of age and
adolescents were more likely to be on statins in
the presence of a family history of early heart
disease and higher low-density lipoprotein
cholesterol.
▸ In only 64% of children the family mutation
was known.
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criteria for FH probands in the general population are too strin-
gent for use in relatives, given the higher prior probability of a
ﬁrst-degree relative having FH (50% vs 1/500). To overcome
this, sex-speciﬁc LDL-C diagnostic cut-offs were established7
designed to give the greatest overall accuracy when testing rela-
tives of patients with FH in the absence of a genetic diagnosis,
and their use was recommended by NICE CG71. However,
mutation testing is recommended as the unambiguous ideal
cascade screening test for FH.
In adults with FH, an underlying genetic cause for the dis-
order can be identiﬁed in ∼80% of DFH cases,8 and is most
often attributable to mutations within the LDLR gene which
encodes the low-density lipoprotein receptor. Mutations in apo-
lipoprotein B and proprotein convertase subtilisin/kexin type 9
can produce phenotypes identical to LDLR FH.9 In the majority
of patients where no causative mutation can be found a poly-
genic cause of their hyperlipidaemia is most likely.10 11
Over the last 5 years several countries have produced guide-
lines for the identiﬁcation and management of adults and chil-
dren with FH.1 12–15 All of them recommend the use of
lipid-lowering statin therapy in children, but the age at which
statin use should be started, or its intensity, to best prevent the
onset of adult premature CHD has not been established, since
there are no long-term randomised controlled outcome trials
for ethical reasons. By contrast there is considerable short-term
randomised and observational data available on the management
of children with HeFH, showing a good safety proﬁle, without
liver toxicity side effects, no inﬂuence on growth trajectory and
excellent efﬁcacy in terms of LDL-C reduction over periods of
2–3 years.16 17
Children with HeFH have roughly twice the normal LDL-C
levels from birth and thus their LDL-C burden (average
level×years of age) increases at twice the rate of their non-FH
siblings16 (see ﬁgure 1). As a consequence of this they develop
atherosclerosis that is detectable as signiﬁcant carotid intima
media thickness (CIMT) as compared with their siblings by the
age of 10 years.18 19 In a randomised controlled trial of the use
of pravastatin, further change in CIMT was prevented.20 Based
on this data the NICE guidance is that the use of statins should
be considered in children with HeFH by the age of 10 years
using clinical judgement, based on the child’s LDL-C level, the
age of onset of CHD in the parent or relatives, and the presence
of other CHD risk factors.
The National Paediatric FH Register was established in 2012.
The aim of this register is to collect baseline and long-term
follow-up data on all children with FH in UK, to document
how well current NICE guidance on the diagnosis and manage-
ment of children with HeFH is being adhered to, and to deter-
mine the safety and efﬁcacy of statins commenced below the age
of 16 years. We report here the preliminary results on the ﬁrst
232 registered children.
METHODS
The register steering committee includes a patient representa-
tive, adult and child physicians and representatives of Heart UK,
British Heart Foundation, British Inherited Metabolic Disease
Group, and the Royal College of Paediatrics and Child Health.
An electronic web based data capture tool was developed to
provide comparative audit and long-term safety data, and anon-
ymised data for research (see online supplementary appendix 1).
The Royal College of Physicians (RCP) currently acts as the host
server for the register. All lipid clinics in England and paediatri-
cians with an interest in lipid disorders were contacted and
details of the register provided. To enrol patients each centre
was provided with a centre-speciﬁc code and password.
Statistical methods
Results for continuous variables are presented as mean (±SD)
and median (with IQR), and differences by sex and statin use
are tested using Mann-Whitney U tests. Differences in height,
weight and the fall in LDL-C by statin use are adjusted for age
using analysis of covariance. Categorical variables are presented
as percentages and number, and tested using χ2 tests or Fisher’s
exact test. Changes in LDL-C by statin use were analysed using
analysis of covariance with adjustment for age and length of
follow-up. Differences in the effect of statin by age group were
tested by including an interaction term in the model. Cox pro-
portional hazards models are used to take account of the length
of follow-up as well as age at diagnosis when looking at time to
statin commencement. Statin-induced toxicity was examined as
the proportion of children having levels over 2.5×the upper
limit of normal as described in the Common Terminologies
Criteria for Adverse Events guidelines (see online supplementary
table S4 for details).
RESULTS
Data was analysed from July 2012 to November 2014.
Twenty-eight centres have thus far enrolled patients (see online
supplementary appendix 2). Recruitment rates vary from 1 to
29 patients per centre (median 5 patients). The majority of
patients have a diagnosis of HeFH (98.7% (232/235)), while 3
individuals had a TC >15 mmol/L compatible with a diagnosis
of homozygous FH, and were excluded from the analysis. The
majority were white Caucasian (n=185; 78.7%), 10.6% were of
Indian subcontinent origin (n=25). Only four of the individuals
(1.7%) were reported as cigarette smokers.
Since NICE CG71 recommends testing of children at risk of
HeFH by the age of 10 years, we present the characteristics of
the registered children divided into those below and above this
age (table 1). Of the 232 HeFH children registered, there are
equal numbers of boys and girls (50% boys). Overall, the
untreated mean (±SD) TC was 7.61(1.48) mmol/L and LDL-C
of 5.67 (1.46) mmol/L (ﬁgure 1), with levels of high-density
lipoprotein cholesterol (HDL-C) and triglycerides (TG) within
the normal range. Three of the children had a TG level
>3.5 mmol/L but this had fallen to below 2.0 mmol/L at
Figure 1 Histogram of the measured total cholesterol and
low-density lipoprotein cholesterol (LDL-C) in the children with
heterozygous familial hypercholesterolaemia (HeFH).
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follow-up suggesting that initial levels may not have been from a
fasting blood sample.
We ﬁrst examined to what extent the registered children ful-
ﬁlled the NICE recommended LDL-C cut-off criteria.7 Only
2.6% of the children had LDL-C below the age-recommended
and gender-recommended diagnostic cut-off for HeFH, with an
additional 2.1% having levels in the ‘grey’ zone of undeter-
mined FH status. Thus at diagnosis 95.3% had LDL-C levels
above the age-adjusted and sex-adjusted cut-offs for FH status.
This did not differ signiﬁcantly between boys and girls (not
shown).
We next examined the differences in baseline characteristics
between those who were subsequently prescribed statin at a
follow-up visit at the last data cut-off for analyses (November
2014). Interestingly, table 1 and (ﬁgure 2) shows that the mean
TC and LDL-C levels were signiﬁcantly lower at registration in
the children above 10 years, with (see online supplementary
ﬁgure S1) a signiﬁcant negative correlation between age and
TC (R=−0.30, p=8.4×10−06) and age and LDL-C levels
(R=−0.34, p=1.4×10−06). One possible explanation for this is
that the younger children are more likely to be referred in light
of a family history of early onset of CHD or a higher plasma
level of LDL-C at diagnosis, while adolescents with a family
history of FH are more likely to be referred to a lipid clinic
regardless of their TC or LDL-C level.
Overall 111/232 (47.8%) of the children were on statins.
Children over the age of 10 years at the most recent follow-up
were twice as likely to be on statin treatment than those under
10 years (57.6% (102/177) vs 23.1% (9/39), p=0.00009).
There were no signiﬁcant differences in gender by statin use and
girls were commenced on statins at a median age of 11.8 years
compared with 11.2 years in boys (p=0.91). In those who sub-
sequently were started on statin treatment, there was non-
signiﬁcant evidence in both age groups of a greater family
history of early CHD in a parent or ﬁrst-degree relative and, in
the sample as a whole, family history of CHD in any relative
was signiﬁcantly more common in those subsequently started on
statin treatment, with 48.7% (54/111) of those on statins having
a family history in any relative compared with 33.9% (41/121)
of those not on statins (p=0.02). In children where the family
mutation was recorded as known or not known, there was no
difference in the proportion with subsequent statin use (table 2).
We also examined the possibility that the 15 registering
centres that are purely paediatric (97 children) might be pre-
scribing statin therapy at a different rate from the 13 clinics
seeing both adults and children (135 children). After adjustment
for age >10 years, the HR (95% CI) for being on a statin was
2.34 (1.32 to 4.15) for those seen at a paediatric clinic
(p=0.004). To examine the relative contributions of these
characteristics in determining statin use we carried out a Cox
proportional hazards models for time to statin prescription with
adjustment for age at diagnosis, and HRs (95% CIs) are pre-
sented in online supplementary table S2 and as a Kaplan-Meier
curve by tertiles of LDL-C in ﬁgure 2. After adjustment for age
at diagnosis, diagnostic cholesterol (1.52 (1.26 to 1.84) per 1
SD increase), LDL-C (1.59 (1.28 to 1.96) per 1 SD increase)
and clinic type (HR 2.39 95% CI 1.57 to 3.65) were signiﬁ-
cantly associated with time to commencement of statin use (all
p<0.0001).
As shown in ﬁgure 3 in both age groups the diagnostic LDL-C
in those who were subsequently treated was signiﬁcantly higher
than in those not currently on statins. Change in LDL with
statin use did not differ between age groups (age by statin inter-
action, p=0.45). Overall, LDL-C levels in the statin-treated chil-
dren fell by an average of 2.07 mmol/L (35%) achieving levels
of 3.93 (1.11) mmol/L compared with 6.01 (1.46) mmol/L, a
fall of 5.4% (0.29 (0.87) mmol/L) in the untreated group
(p=1.2×10−19) (table 2 and ﬁgure 2). This difference remained
after adjustment for diagnosis age and length of follow-up (esti-
mated mean change (SE) 2.07 (0.12) for the treated group
versus −0.25 (0.12) for the untreated group, p=1.1×10−16).
However, there was a wide range in the fall of LDL-C levels
from baseline, ranging from a 63% fall to a 15% rise in the
statin-treated group, and from a 40% fall to a 50% rise in the
untreated group. (For details on the statins prescribed see online
supplementary table S2).
We addressed the issue of safety of statin use by analysing the
measures of plasma creatine kinase (CK), alanine aminotransfer-
ase (ALT) and aspartate aminotransferase (AST) at follow-up.
Table 1 Paediatric FH Register characteristics* at baseline by age
≤10 years
N=96†
>10 years
N=111†
Number boys/girls
(%age boys)
50/46 (52.1) 54/57 (48.7)
Age (years) Mean (SD) N
Median (IQR)
7.3 (2.2) 96
7.8 (5.5–9.1)
12.6 (1.7) 111
12.6 (10.9–13.9)
Weight (kg) Mean (SD) N
Median (IQR)
27.8 (9.5) 88
25.6 (21–34.1)
50.3 (14.4) 102
49.1 (40.5–57.7)
Height (m) Mean (SD) N
Median (IQR)
1.26 (14.2) 77
1.28 (1.17–1.37)
1.56 (11.4) 91
1.55 (1.49–1.64)
Total cholesterol
(mmol/L)
Mean (SD) N
Median (IQR)
8.07 (1.43) 96
8.0 (6.99–9.15)
7.22 (1.43) 111‡
7.1 (6.3–8.0)
LDL-C (mmol/L) Mean (SD) N
Median (IQR)
6.17 (1.40) 87
6.1 (5.1–7.1)
5.28 (1.39) 106§
5.1 (4.4–6.1)
HDL-C (mmol/L) Mean (SD) N
Median (IQR)
1.41 (0.35) 87
1.4 (1.13–1.65)
1.41 (0.33) 105
1.4 (1.2–1.6)
Triglyceride (mmol/L) Mean (SD) N
Median (IQR)
0.96 (0.47) 86
0.84 (0.7–1.1)
1.04 (0.60) 103
0.90 (0.67–1.25)
Smoking % (N) 1.04% (1/96) 2.7% (3/110)
There are 31 adolescent girls on statins. Five do not have oral contraceptive use
recorded. Four of the remaining 26 (15%) were prescribed oral contraceptives.
*Excluding 3 patients with homozygous FH.
†25 children are missing diagnosis dates.
‡Cholesterol is significantly lower in age>10 years versus age<10 years, p=0.00006.
§LDL-C is significantly lower in age>10 years vs age<10 years, p=0.00001
FH, familial hypercholesterolaemia; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol.
Figure 2 Kaplan-Meier plot for being treated with statin by tertile of
baseline low-density lipoprotein cholesterol (LDL-C). Tertile cut-offs
were Tertile 1 ≤4.9 mmol/L, Tertile 2 >4.9 and ≤6.1 mmol/l, Tertile 3
>6.1 mmol/L.
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Table 2 Characteristics at diagnosis by age at diagnosis and subsequent statin use
Age ≤10 years
Statin use
p Value (Mann-Whitney)
No
N=51
Yes
N=45
Age (years) Mean (SD)
Median (IQR)
7.4 (2.0) 51
7.7 (5.6–8.9)
7.1 (2.5) 45
7.8 (5.3–9.3)
0.84
Sex % male 47.1% (24/51) 57.8% (26/45) 0.29 (χ2)
Ethnicity % Caucasian 78.4 (40/51) 84.4 (38/45) 0.45 (χ2)
CHD in parent/first-degree relative % yes 15.7% (8/51) 22.7% (10/44) 0.38(χ2)
CHD in any relative %yes 33.3% (17/51) 48.9% (22/45) 0.12 (χ2)
CHD onset age in relative Mean (SD)
Median (IQR)
33.9 (20.5) 17
40 (30–49)
33.7 (16.8) 22
40 (23–44)
0.68
Mutation status % yes 58.7% (27/46) 60.5% (26/43) 0.87 (chi-square)
Diag weight (kg) Mean (SD)
Median (IQR)
27.6 (9.5) 48
24.6 (21.4–32.5)
27.9 (9.6) 40
27.4 (20.4–34.4)
0.85
Diag height (m) Mean (SD)
Median (IQR)
1.25 (0.14) 43
1.27 (1.17–1.36)
1.27 (0.14) 34
1.29 (1.20–1.38)
0.64
Diag cholesterol (mmol/L) Mean (SD)
Median (IQR)
7.77 (1.42) 51
7.6 (6.8–8.4)
8.40 (1.39) 45
8.5 (7.3–9.3)
0.01
Diag HDL-C (mmol/L) Mean (SD)
Median (IQR)
1.44 (0.38) 47
1.4 (1.13–1.7)
1.37 (0.31) 40
1.39 (1.13–1.59)
0.62
Diag triglyceride (mmol/L) Mean (SD)
Median (IQR)
0.94 (0.54) 46
0.8 (0.64–1.1)
0.99 (0.39) 40
0.9 (0.76–1.18)
0.12
Diag LDL-C (mmol/L) Mean (SD)
Median (IQR)
5.83 (1.30) 48
5.8 (4.85–6.42)
6.59 (1.42) 39
6.7 (5.5–7.7)
0.008
Follow-up weight (kg) Mean (SD)
Median (IQR)
35.5 (14.3) 48
32.0 (25.1–42.6)
43.8 (17.1) 44
37.2 (33.6–55.2)
0.005
Follow-up height (m) Mean (SD)
Median (IQR)
1.34 (0.116) 41
1.37 (0.126–1.42)
1.46 (0.18) 41
1.46 (1.38–1.57)
0.0006
Follow-up cholesterol (mmol/L) Mean (SD)
Median (IQR)
7.34 (1.37) 48
7.2 (6.4–8.3)
5.82 (0.92) 53
5.8 (5.1–6.3)
1.484e-07
Follow-up HDL-C (mmol/L) Mean (SD)
Median (IQR)
1.42 (0.33) 43
1.4 (1.13–1.68)
1.38 (0.37) 43
1.37 (1.16–1.52)
0.47
Follow-up triglyceride (mmol/L) Mean (SD)
Median (IQR)
0.94 (0.54) 42
0.8 (0.6–1.2)
0.91 (0.38) 42
0.82 (0.68–1.01)
0.87
Follow-up LDL-C (mmol/L) Mean (SD)
Median (IQR)
5.47 (1.26) 45
5.3 (4.6–6.45)
4.06 (0.97) 41
4.02 (3.3–4.6)
1.316e-06
Age>10 years
No
N=46
Yes
N=65 P value (Mann-Whitney)
Age (years) Mean (SD)
Median (IQR)
12.8 (1.7) 46
12.9 (11.1–14.0)
12.5 (1.7) 65
12.2 (10.8–13.8)
0.35
Sex % male 50.0% (23/46) 47.7% (31/65) 0.81 (χ2)
Ethnicity % Caucasian 76.1 (35/46) 83.1 (54/65) 0.36 (χ2)
CHD in parent/first-degree relative % yes 23.9% (11/46) 32.8% (21/64) 0.31 (χ2)
CHD in any relative %yes 41.3% (19/46) 49.2% (32/65) 0.41 (χ2)
CHD onset age in relative Mean (SD)
Median (IQR)
44.2 (11.5) 22
46 (36–52)
41.8 (11.5) 35
40 (37–48)
0.46
Mutation status % yes 56.8% (21/37) 71.2% (42/59) 0.15 (χ2)
Diag weight (kg) Mean (SD)
Median (IQR)
51.5 (13.1) 43
49.2 (41.9–59.4)
49.4 (15.4) 59
48.6 (38–56.4)
0.35
Diag height (m) Mean (SD)
Median (IQR)
1.58 (0.10) 39
1.56 (1.51–1.67)
1.54 (0.12) 52
1.54 (1.48–1.64)
0.23
Diag cholesterol (mmol/L) Mean (SD)
Median (IQR)
6.73 (1.37) 46
6.6 (5.8–7.5)
7.57 (1.38) 65
7.43 (6.8–8.3)
0.001
Diag HDL-C (mmol/L) Mean (SD)
Median (IQR)
1.42 (0.37) 42
1.35 (1.2–1.6)
1.41 (0.30) 63
1.4 (1.2–1.6)
0.81
Diag triglyceride (mmol/L) Mean (SD)
Median (IQR)
1.03 (0.58) 41
0.8 (0.7–1.2)
1.04 (0.62) 62
0.9 (0.6–1.3)
0.85
Diag LDL-C (mmol/L) Mean (SD)
Median (IQR)
4.76 (1.28) 44
4.65 (4–5.4)
5.64 (1.37) 62
5.5 (4.7–6.4)
0.0007
Follow-up weight (kg) Mean (SD)
Median (IQR)
55.4 (14.3) 44
52.9 (43.9–63.3)
58.8 (14.7) 64
57.1 (50.9–62.7)
0.22
Follow-up height (m) Mean (SD)
Median (IQR)
1.59 (0.10) 34
1.57 (1.53–1.65)
1.63 (0.11) 53
1.63 (1.55–1.70)
0.05
Continued
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None of those on statin had measured plasma levels of CK, ALT
and AST indicative of statin toxicity (ie, >2.5 times the normal
range) (see online supplementary table 4 and ﬁgure S2).
DISCUSSION
The primary aim of this register is to collect baseline and long-
term follow-up data on all children with FH in the UK, to see
how well current NICE guidance on the diagnosis and man-
agement of children with HeFH is being adhered to, and to
determine the safety and efﬁcacy of lipid-lowering therapies,
particularly when commenced below the age of 16 years. The
children examined here have similar characteristics to the 147
children with data collected in the 2010 national FH audit,21
where the mean (IQR) LDL-C was 5.4 (4.5–6.1) mmol/L,
HDL-C was 1.3 (1.1–1.6) mmol/L and TG 0.9 (0.7–1.2)
mmol/L.5 It therefore appears that the children being entered
onto the register are representative of those being seen in UK
lipid clinics. Since essentially all of the registered children had
been identiﬁed by family screening, the appropriate diagnostic
LDL-C levels for HeFH are the NICE-recommended age and
sex-speciﬁc cut-offs,7 and using these, at diagnosis, 95.3% had
LDL-C levels above the age and sex cut-offs for being HeFH.
Although NICE CG71 recommends DNA testing for all indivi-
duals with a diagnosis of HeFH; FH causing mutations were
documented in 64% of children, the majority with a family
mutation identiﬁed. While some families may not have con-
sented to a genetic test, the reason for not performing a
genetic test in children is primarily due to the lack of availabil-
ity/funding of such tests in some parts of the country.
Since NICE recommends consideration of a statin for both
boys and girls by the age of 10 years, the children were divided
into those below 10 years (where only those with a poor family
history of CHD or extreme LDL-C are expected to have been
prescribed a statin) and those above 10 years when the majority
would be expected to be on a statin. The data conﬁrms that use
of statins in early childhood and adolescence is primarily inﬂu-
enced by the age of the patient, the diagnostic level of TC and
LDL-C, which are the major determinants of future risk of ath-
erosclerosis, and of having a history of CHD in a parent or rela-
tive. Knowing the family mutation did not appear to inﬂuence
commencing lipid-lowering drugs. Reassuringly, and as recom-
mended by NICE CG71, girls were as likely as boys to have
been started on statin therapy. Over 90% of those children pre-
scribed a statin were taking a modest dose of 20 mgs or less, but
reductions of LDL-C levels in the treated group were substantial
(32–38%). Children often only require a low dose of statin to
achieve a signiﬁcant effect on LDL-C, compared with the sorts
of doses (and potency) of statins being prescribed in adult FH
clinics.12–15
There are currently no evidence-based recommendations on
the optimal LDL-C reduction or level in children necessary to
prevent the early development of signiﬁcant atherosclerotic
disease and subsequent cardiovascular events. The treated chil-
dren demonstrated a mean 35% overall decrease in LDL-C but
with a large range due presumably to different potency, compli-
ance to treatment and dose of statin used. With the small number
of patients currently available, a more detailed analysis is not pos-
sible. With respect to growth parameters, there was no signiﬁcant
difference in mean changes in cross-sectional weight and height
in treated versus non-treated children, but a more appropriate
analysis will be available when annual follow-up information is
available. None of the children on statin treatment had evidence
of statin toxicity as determined by measures of CK, ALTor AST.
One of the limitations of the Register is that by its nature it is
an opportunistic sample and is likely to be biased to children
with HeFH from more severely affected families than HeFH
children in the general population. We also do not have data on
the capture rate, recruitment rate, consent rate and retention for
this register, or have details on any side effects of statin treat-
ment such as muscle aches, and we are unaware of any similar
FH children’s register worldwide for other comparisons. We are
currently working with the recruiting clinicians to ensure that as
few as possible of the children are lost to follow-up as they tran-
sition to adulthood.
Table 2 Continued
Age>10 years
No
N=46
Yes
N=65 P value (Mann-Whitney)
Follow-up cholesterol (mmol/L) Mean (SD)
Median (IQR)
6.52 (1.33) 46
6.3 (5.6–7.1)
5.55 (1.22) 65
5.3 (4.72–6.3)
0.0004
Follow-up HDL-C (mmol/L) Mean (SD)
Median (IQR)
1.44 (0.36) 45
1.43 (1.2–1.6)
1.37 (0.27) 57
1.38 (1.2–1.5)
0.36
Follow-up triglyceride (mmol/L) Mean (SD)
Median (IQR)
1.04 (0.49) 44
0.90 (0.7–1.30)
0.97 (0.50) 58
0.82 (0.6–1.2)
0.33
Follow-up LDL-C (mmol/L) Mean (SD)
Median (IQR)
4.55 (1.27) 44
4.3 (3.8–5.1)
3.82 (1.21) 55
3.6 (2.9–4.8)
0.006
CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Figure 3 Change in low-density lipoprotein cholesterol (LDL-C) from
baseline to follow-up value in children below and above the age of
10 years. The overall 5.4% reduction from LDL-C levels at diagnosis to
follow-up in the children not being treated with statin may simply
represent a regression to the mean effect, or possibly due to the effect
of dietary fat restriction following dietician advice.
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